Logo

The US FDA Approves Allecra Therapeutics' Exblifep for the Treatment of Complicated Urinary Tract Infections (cUTIs)

Share this
Allecra Therapeutics

The US FDA Approves Allecra Therapeutics' Exblifep for the Treatment of Complicated Urinary Tract Infections (cUTIs)

  • The US FDA has granted approval to the company’s Exblifep for the treatment of complicated urinary tract infections (incl. pyelonephritis) patients (18yrs. & above) along with a 5-yr. marketing exclusivity extension until 2032 
  • The approval was based on clinical data that showed the effectiveness of Exblifep against antimicrobial resistance in gram –ve bacteria, especially resistance mediated by both ESBL and AmpC and data from the P-III (ALLIUM) study which met the 1EP of non-inferiority and superiority with the drug vs piperacillin/tazobactam  
  • Shanghai Haini Pharmaceutical is the drug’s exclusive license holder across Greater China and Advanz Pharma in the EU region 

Ref: Allecra Therapeutics | Image: Allecra Therapeutics

Related News:- Everest Medicines Receives the NMPA Recommendation of Priority Review for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions